• 1
    Cosio FG, Kudva Y, Velde M et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 24152421.
  • 2
    Sumrani NB, Delaney V, Ding ZK et al. Diabetes mellitus after renal transplantation in the cyclosporine era: An analysis of risk factors. Transplantation 1991; 51: 343347.
  • 3
    Vesco L, Busson M, Bedrossian J et al. Diabetes mellitus after renal transplantation. Transplantation 1996; 61: 14751478.
  • 4
    Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: A systematic review of the literature. Diabetes Care 2002; 25: 583592.
  • 5
    Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977983.
  • 6
    Hirano Y, Hisatomi A, Ohara K, Noguchi H. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. Transplantation 1992; 54: 883887.
  • 7
    Tamura K, Fujimura T, Tsutsumi T et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding-protein-12 in pancreatic (beta)-cell. Transplantation 1995; 59: 16061613.
  • 8
    Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 2003; 75 (Suppl): SS324.
  • 9
    Baldwin D, Duffin KE. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation 2004; 77: 10091014.
  • 10
    Pietruck F, Kribben A, Ngo Van T et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int 2005; 18: 483486.
  • 11
    Marceille JR, Goins JA, Soni R, Biery JC, Lee TA. Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. Pharmacotherapy 2004; 24: 13171322.
  • 12
    Fonarow GC. Approach to the management of diabetic patients with heart failure: Role of thiazolidinediones. Am Heart J 2004; 148: 551558.
  • 13
    Yale JF. Oral antihyperglycemic agents and renal disease: New agents, new concepts. J Am Soc Nephrol 2005; 16 (Suppl 1): S7S10.
  • 14
    Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 2003; 56: 305324.
  • 15
    Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997; 20: 18222826.
  • 16
    Standl E, Füchtenbusch M. The role of oral antidiabetic agents: Why and when to use an early-phase insulin secretion agent in type 2 diabetes mellitus. Diabetologica 2003; 46 (Suppl): M30M36.
  • 17
    Plosker GL, Figgitt DP. Repaglinide: A pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics 2004: 389411.
  • 18
    Thervet E, Legendre C, Beaune P, Anglicheau D. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005; 6: 3747.